United States

People: Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

21 Mar 2018
Change (% chg)

$-0.79 (-3.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Law, Deborah 

Dr. Deborah Law, D. PHIL., is the Chief Scientific Officer at Jounce Therapeutics, Inc. Debbie Law brings to Jounce nearly two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology. Dr. Law joined Jounce from Merck, where she most recently served as vice president of therapy area biology for immunology, oncology and immunomodulators. There, she was responsible for bringing cancer immunotherapy compounds from discovery to the clinic. Prior to Merck, Dr. Law served as the chief scientific officer for Ablynx n.v. and held various research positions in biotechnology companies including PDL Biopharma, EOS Biotechnology and Cor Therapeutics. Dr. Law holds a B.S. in immunology from Glasgow University, a D. Phil. in immunology from Oxford University and pursued postdoctoral research at University of California San Francisco.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --